Stocktoria
ELUTIA INC. ELUT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-08
ELUTIA INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 53.7% | 46.4% | 44.7% | 48.8% | 40.1% |
| Operating margin | -218.9% | -212.3% | -123.4% | -147.5% | -48.6% |
| Net margin | 434.2% | -372.9% | -152.2% | -137.9% | -52.4% |
| FCF margin | -379.8% | -161.1% | -89.3% | -92.1% | -33.4% |
| Return on assets | 85.6% | -149.3% | -86.7% | -47.8% | -37.0% |
| Return on equity | 192.9% | 116.6% | 97.6% | 653.6% | -183.7% |
| Debt / equity | — | -0.52× | -0.61× | -4.82× | 1.37× |
| Current ratio | 2.22 | 0.69 | 0.73 | 1.19 | 1.82 |
| Revenue growth | -15.0% | -41.5% | 3.8% | -49.7% | 11.0% |
Source: SEC EDGAR filings · CIK 0001708527 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.